Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

The goal of this clinical trial is to learn if Venetoclax+Azacytidine+Quizartinib works better than standard therapy (Venetoclax+Azacytdine) to treat naïve adult patients with acute myeloid leukemia (AML) who are not suitable for standard induction therapy due to age, co-morbidities or other risk factors. The main question it aims to answer is: \- Does the combination of Venetoclax+Azacytidine+Quizartinib show more probability of overall survival than Venetoclax+Azacytdine? Researchers will compare Venetoclax+Azacytidine+Quizartinib to Venetoclax+Azacytdine to see if Venetoclax+Azacytidine+Q

Trial Details

NCT ID
NCT07478991
Phase
PHASE3
Sponsor
PETHEMA Foundation
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Venetoclax
  • Quizartinib
Locations (sample)
  • Santiago de Compostela, A Coruña, Spain|42.88052,-8.54569
  • Hospitalet Del Llobregat, Barcelona, Spain
  • Jaén, Jaen, Spain|37.76922,-3.79028
  • Alcalá de Henares, Madrid, Spain|40.48205,-3.35996
  • Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • The subject must have confirmation of AML by 2022 WHO criteria, previously untreated and be ineligible for treatment with a standard cytarabine and…
  • Patients must be considered ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age or co-morbidities de…
  • ≥ 75 years of age;
  • or ≥ 18 to 75 years of age with at least one of the following co-morbidities:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →